UnitedHealthcare · Hereditary Cancer Panel · US health-plan appeal rights

Hereditary Cancer Panel denied as duplicate or overlapping therapy by UnitedHealthcare?

Q: How long do I have to appeal a UnitedHealthcare Hereditary Cancer Panel denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-09

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What UnitedHealthcare typically requires

UnitedHealthcare's specific coverage criteria for hereditary cancer panel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: UHC Genetic Testing for Hereditary Cancer Susceptibility Syndromes (Optum Genetic Testing Solution)

The UnitedHealthcare angle on Hereditary Cancer Panel

## Why UnitedHealthcare Denied Your Hereditary Cancer Panel as Duplicate Therapy

UnitedHealthcare (UHC) uses its own clinical coverage policies — published under the "Coverage Determination Guideline" framework — to evaluate hereditary cancer panel requests. A duplicate-therapy denial means UHC's claims system has identified a prior genetic test that it considers equivalent to the panel now being requested, and its policy does not cover the same or substantially similar testing twice.

This denial is frequently incorrect or overstated, and it is among the more routinely overturned denial types when properly documented.

## Why This Denial Is Appealable

Genetic panels are not clinically interchangeable. A prior single-gene test, a smaller panel, or an older multi-gene panel does not cover the same clinical ground as a current comprehensive hereditary cancer panel. Gene sets differ by laboratory, platform, and guideline era. A prior test that returned negative or uninformative results on a subset of genes does not preclude meaningful new findings from a broader or updated panel. UHC's own clinical coverage guidelines distinguish between prior testing scope and current medically necessary testing — your appeal must make that distinction explicit and document it.

## Federal Appeal Framework

Internal Appeal: ACA and ERISA §503 provide the right to a full-and-fair internal appeal. File within the deadline stated on your denial notice (typically 180 days for ERISA plans).
External Review: Under ACA §2719, after a final internal denial, most members are entitled to independent external review by an accredited IRO, generally within four months. Expedited external review is available for urgent situations.
ERISA Plans: Request the complete claims file, the specific Coverage Determination Guideline applied, and the Summary Plan Description before drafting your appeal.

## Concrete Appeal Steps and Timeline

1. Request the denial rationale and the specific prior test UHC identified — confirm whether they have the correct prior test in their records. 2. Pull the complete prior test report — document the exact genes tested, methodology, date, and laboratory. 3. Have your prescriber compare the prior test's gene set to the currently ordered panel and document the clinical gap. 4. File internal appeal within the stated deadline. 5. File external review if internal appeal is upheld.

## Documentation to Gather

Complete prior test report with exact gene list, laboratory name, and date
Side-by-side comparison of prior gene set versus current panel gene set (your laboratory or ordering provider can prepare this)
Prescriber letter documenting why the current panel is clinically distinct and necessary despite the prior test
New clinical or family history information that has emerged since the prior test, if applicable
Current applicable guideline from the relevant professional organization (such as NCCN) supporting the specific panel for your indication — obtain the current version directly from that organization

## Criteria-Mapping Structure

For each requirement in UHC's coverage guideline, document the chart fact:

| Policy Requirement | Your Supporting Evidence | |---|---| | No prior equivalent test on file | Prior test report showing different gene set; gene-set comparison document | | New clinical indication or changed clinical picture | Updated family history, new diagnosis records, VUS reclassification | | Current panel is medically necessary | Prescriber letter; guideline support for specific panel ordered |

UHC reviewers respond well to precise, side-by-side gene-set comparisons — if the prior test covered 5 genes and the current panel covers many more, that document alone can be the deciding factor in an internal appeal.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other UnitedHealthcare appeals

Other insurers on Hereditary Cancer Panel

Other denial reasons for UnitedHealthcare Hereditary Cancer Panel

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-09. Editorial standards: denialhelp.com/authors.